65,437 trials
Myelodysplastic Syndrome · MDS
Primary: Mean Decitabine Area Under the Concentration Versus Time Curve (AUC0-t) on Day 5 by Cohort in Phase 1 — 53.6; 68.9; 94.8; 221 ng*h/mL
Duchenne Muscular Dystrophy · Spinal Muscular Atrophy · Congenital Muscular Dystrophy
Primary: Geometric Mean Titer Ratio for Each Vaccine Strain — 3.76; 3.53; 2; 1.46 geometric mean titer ratio — p=<.05
Hemophagocytic Lymphohistiocytosis
Primary: Overall Survival — 25 Participants
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) — 0.11; 0.22 number of relapses in a year — p=<0.001
Fatty Liver
Primary: Biochemical: Number of Patients With Normal Transaminases at End of Treatment. — 6; 6; 6 Participants
Sickle Cell Anemia
Primary: End-Tidal Carbon Monoxide — 4.35; .80 ppm
Carotid Stenosis
Primary: Radical Peripapillary Capillaries Vessel Density — 55.95; 57.24 percentage of vessel
Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response…
Viral Intestinal Infection
Primary: Average Diarrhea Duration. — 43.4; 54.7 hours — p=0.004
Fatigue in Multiple Sclerosis
Primary: Modified Fatigue Impact Scale (MFIS) Score — 40.6; 41.3; 39.0; 38.6 score on a scale
Intravitreal Injections · IVI
Primary: McGill Pain Questionnaire (SF-MPQ) Scores at Baseline — 0.62; 0.93; 0.53 score on a scale
Nocturnal Enuresis
Primary: Change in Number of Dry Nights When Using the Scheduled Awakening Protocol With the Lully Sleep Guardian — -0.67 difference in number of dry nights
Leukemia
Primary: Number of Patients Treated With Alemtuzumab and Rituximab Combination With a Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Lymph-adenopathy and Organomegaly…
Covid19
Primary: Number of Infected Subjects — 0; 11 Participants — p=< 0.0001
Social Skills · Self-Criticism · Post-traumatic Stress Disorder
Primary: Negative Social Reactions — 1.25; 1.28; 1.35 Mean of actual negative reactions scale